This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT) | MicrobiomeTrials
← Back to trials NCT05404139
Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT) Recruiting PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2023-05-24Est. Completion: 2031-02
Enrollment target: 352 participantsLocations Princess Margaret Cancer Center, Toronto, Ontario, Canada Sunnybrook Research Institute, Toronto, Ontartio, Canada Other microbiome trials you might be interested in Metastatic Solid Tumor Recurrent Solid Tumor Advanced Solid Tumor Urinary Bladder Neoplasm Triple Negative Breast Cancer Non-small Cell Lung Cancer Esophageal Cancer Pancreatic Cancer Ovarian Cancer Cervical Cancer Head and Neck Squamous Cell Carcinoma Prostate Cancer Renal Pelvis Cancer Bladder Cancer
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in particip…
Duarte, United States Est. completion May 2027
Advanced/Metastatic Solid Tumors
This is a multicenter, open-label, multiple-dose, FIH Phase 1a/1b study. Phase 1a adopts an accelerated titration design…
Los Angeles, United States Est. completion Jun 2028